Chiasma Reports on Significant Progress Made During 2017
January 08, 2018 09:00 ET
|
Chiasma, Inc.
Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDAAnnounces expected year-end 2017 cash and investments balance of approximately $67 millionContinues to expect existing cash...
Chiasma Reports Third Quarter 2017 Results
November 09, 2017 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Recognizes Acromegaly Awareness Day
November 01, 2017 08:50 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
September 27, 2017 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Second Quarter 2017 Results
August 10, 2017 16:01 ET
|
Chiasma, Inc.
WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
August 10, 2017 16:00 ET
|
Chiasma, Inc.
Chiasma plans to initiate enrollment in the new Phase 3 clinical trial – OPTIMAL – during second half of 2017Anticipates release of top-line data from new OPTIMAL trial by end of 2019Conference call...
Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors
June 19, 2017 08:18 ET
|
Chiasma, Inc.
WALTHAM, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports First Quarter 2017 Results
May 05, 2017 08:00 ET
|
Chiasma, Inc.
WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire
March 30, 2017 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Fourth Quarter and Year End 2016 Results
March 16, 2017 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...